Deal Lead: Dr Paul Kelly
Background
Vaxxas is developing a new medical device for vaccine delivery using a game-changing micro needle technology (NanopatchTM) developed at the University of Queensland. The Nanopatch:
targets the key intradermal site for vaccine delivery;
generates a better immune response than traditional needle and syringe;
is painfree (no needles);
- may avoid the need for adjuvants and the refrigeration of vaccines.
The technology is targeting a multi-billion market and is already receiving strong interest from big pharmaceutical companies for use with their vaccines.
Our Partnership
Vaxxas founder and director Professor Mark Kendall is the inventor of the Nanopatch. OneVentures is working alongside Mark and his team at AIBN and University of Queensland to take the technology through product development to first in-human studies and subsequent commercialisation.